{"anticipatedPostingDate":"2027-09","denomUnitsSelected":"Participants","description":"AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per common terminology criteria for adverse events (CTCAE) version 4, Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE.","reportingStatus":"NOT_POSTED","timeFrame":"From start of treatment up to 37 days after last dose of study drug (approximately up to 7.4 years)","title":"Number of Participants With Grade 3-5 TEAE","type":"SECONDARY"}